Patents by Inventor Sandeep Dutta

Sandeep Dutta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210097678
    Abstract: Systems and techniques for generating and/or employing a computed tomography (CT) medical imaging fracture model are presented. In one example, a system employs a first convolutional neural network associated with vertebrae segmentation to generate learned vertebrae segmentation data regarding a spine anatomical region related to a CT image. The system also employs a second convolutional neural network associated with fracture segmentation to generate, based on the learned vertebrae segmentation data, learned fracture segmentation data regarding the spine anatomical region. Furthermore, the system detects presence or absence of a medical fracture condition in the CT image based on the learned vertebrae segmentation data and the learned fracture segmentation data.
    Type: Application
    Filed: September 30, 2019
    Publication date: April 1, 2021
    Inventors: Sandeep Dutta, Ryan Christian King, Bradley Wright, Mitchel Harris, Bharti Khurana, Robert Kevin Moreland
  • Publication number: 20190336565
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 7, 2019
    Publication date: November 7, 2019
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang, Sven Mensing
  • Patent number: 10286029
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 14, 2019
    Assignee: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang, Sven Mensing
  • Publication number: 20190122401
    Abstract: A system and method for estimating vascular flow using CT imaging include a computer readable storage medium having stored thereon a computer program comprising instructions, which, when executed by a computer, cause the computer to acquire a first set of data comprising anatomical information of an imaging subject, the anatomical information comprises information of at least one vessel. The instructions further cause the computer to process the anatomical information to generate an image volume comprising the at least one vessel, generate hemodynamic information based on the image volume, and acquire a second set of data of the imaging subject. The computer is also caused to generate an image comprising the hemodynamic information in combination with a visualization based on the second set of data.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 25, 2019
    Inventors: Robert F. Senzig, Ravikanth Avancha, Bijan Dorri, Sandeep Dutta, Steven J. Gray, Jiang Hsieh, John Irvin Jackson, Giridhar Jothiprasad, Paul Edgar Licato, Darin Robert Okerlund, Toshihiro Rifu, Saad Ahmed Sirohey, Basel Taha, Peter Michael Edic, Jerome Knoplioch, Rahul Bhotika
  • Patent number: 10186056
    Abstract: A system and method for estimating vascular flow using CT imaging include a computer readable storage medium having stored thereon a computer program comprising instructions, which, when executed by a computer, cause the computer to acquire a first set of data comprising anatomical information of an imaging subject, the anatomical information comprises information of at least one vessel. The instructions further cause the computer to process the anatomical information to generate an image volume comprising the at least one vessel, generate hemodynamic information based on the image volume, and acquire a second set of data of the imaging subject. The computer is also caused to generate an image comprising the hemodynamic information in combination with a visualization based on the second set of data.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 22, 2019
    Assignee: GENERAL ELECTRIC COMPANY
    Inventors: Robert F. Senzig, Ravikanth Avancha, Bijan Dorri, Sandeep Dutta, Steven J. Gray, Jiang Hsieh, John Irvin Jackson, Giridhar Jothiprasad, Paul Edgar Licato, Darin Robert Okerlund, Toshihiro Rifu, Saad Ahmed Sirohey, Basel Taha, Peter Michael Edic, Jerome Knoplioch, Rahul Bhotika
  • Publication number: 20180177779
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 7, 2016
    Publication date: June 28, 2018
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Tianli Wang
  • Publication number: 20180177778
    Abstract: The present invention features interferon-free therapies for treating Hepatitis C Virus (HCV) genotypes 1b, 2, 3 or 4. In one aspect, the therapies comprises administering Compound 1 (Paritaprevir), Ritonavir, and Compound 2 (Ombitasvir) to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include the administration of any interferon, and the therapies last from 8 to 12 weeks. Preferably, the therapies do not include the administration of any ribavirin.
    Type: Application
    Filed: June 28, 2016
    Publication date: June 28, 2018
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Tolga Baykal, Barry M. Bernstein, Scott c. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Lino X Rodrigues Jr., Regis A. Vilchez
  • Publication number: 20180085330
    Abstract: This application features dose adjustment for drugs co-administered with glecaprevir and pibrentasvir.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 29, 2018
    Applicant: AbbVie Inc.
    Inventors: Sandeep Dutta, Matthew Kosloski, Wei Liu
  • Publication number: 20180042982
    Abstract: The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 15, 2018
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Tami Pilot-Matias, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Lino Rodrigues Junior, Suvajit Samanti, Roger Trinh, Tianli Wang, Betty B. Yao
  • Patent number: 9811618
    Abstract: A method is provided for simulating a program executable by a processor and a circuit design configured to communicate with the processor. A processor on a programmable IC is configured to execute the program. Programmable resources on the programmable IC are configured to implement a plurality of interface circuits. Each of the interface circuits is configured to communicate data between the processor and a simulation environment using a respective communication protocol. The interface circuits that uses a communication protocol used by the circuit design is enabled and other ones of the interface circuits are disabled. The circuit design is simulated in a simulation environment coupled to the programmable IC. During the simulating, the program is executed on the processor and data is communicated between the processor and the computing platform using the determined one of the plurality of interface circuits.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: November 7, 2017
    Assignee: XILINX, INC.
    Inventors: Umang Parekh, Arvind Sundararajan, Sandeep Dutta
  • Publication number: 20170260264
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half-life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Application
    Filed: September 20, 2016
    Publication date: September 14, 2017
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall
  • Publication number: 20170151238
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 1, 2017
    Applicant: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Tianli Wang
  • Patent number: 9629587
    Abstract: A method is provided including determining at least one range of phases of a cardiac cycle from which to select a selected phase based on at least one of patient demographic information, patient physiological information, or a general physiological model. The method also includes generating corresponding intermediate images for each of the phases of the at least one range of phases. Further, the method includes selecting the selected phase based on at least one image quality (IQ) metric of the intermediate images. Also, the method includes generating an image for diagnostic use using imaging information from the selected phase.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 25, 2017
    Assignee: General Electric Company
    Inventors: Darin Robert Okerlund, Sandeep Dutta, Brian Edward Nett, David Pazzani, Daniel Stassi, Tal Gilat Schmidt
  • Publication number: 20170014348
    Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventors: Joerg Breitenbach, Salih Durak, Sandeep Dutta, Thomas Y. Kessler, Wei Liu, Friedrich W. Richter, Joerg Rosenberg, Gerd Woehrle
  • Publication number: 20160345926
    Abstract: Embodiments are adapted for acquiring projection data from a computed tomography imaging system to form motion-corrected images of cyclically moving imaging subjects. Embodiments determine a start time and time duration of a data record with sufficient data for forming a motion-corrected image from the data record, without screening data records or images for motion artifacts. Some embodiments acquire data asynchronously with respect to the cyclical motion of the imaging subject, without using a signal such as an EKG to select a period of low subject motion for imaging. Other embodiments use a pulse signal synchronized to the imaging subject's motions to reduce an amount of data presented for image reconstruction, or to target a specific phase of the imaging subject's cyclical motion.
    Type: Application
    Filed: December 9, 2015
    Publication date: December 1, 2016
    Inventors: Sandeep Dutta, Ajay Narayanan
  • Publication number: 20160317602
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 1, 2015
    Publication date: November 3, 2016
    Applicant: AbbVie Inc
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang
  • Publication number: 20160317603
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 1, 2015
    Publication date: November 3, 2016
    Applicant: ABBVIE INC.
    Inventors: Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Thomas J. Podsadecki, Tianli Wang
  • Patent number: 9454498
    Abstract: An integrated circuit can include a processor system configured to execute program code. The processor system can be hard-wired and include a processor hardware resource. The IC also can include a programmable circuitry configurable to implement different physical circuits. The programmable circuitry can be coupled to the processor system. The programmable circuitry can be configurable to share usage of the processor hardware resource of the processor system. The processor system further can control aspects of the programmable circuitry such as power on and/or off and also configuration of the programmable circuitry to implement one or more different physical circuits therein.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: September 27, 2016
    Assignee: XILINX, INC.
    Inventors: William E. Allaire, Bradley L. Taylor, Ting Lu, Sandeep Dutta, Patrick J. Crotty, Hassan K. Bazargan, Hy V. Nguyen, Shashank Bhonge
  • Patent number: 9452194
    Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 27, 2016
    Assignee: AbbVie Inc.
    Inventors: Walid M. Awni, Barry M. Bernstein, Scott C. Brun, Daniel E. Cohen, Emily O. Dumas, Sandeep Dutta, Amit Khatri, Cheri E. Klein, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki
  • Patent number: 9447181
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 20, 2016
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall